AM-4030.

AM-4030 is a hybrid cannabinoid: on a fully hydrogenated benzo[c]chromene nucleus, of the hexahydrocannabinol type, with a 1,1-dimethylheptyl chain at position 3 and a hydroxymethyl at position 9, as in HU-243, it carries at position 6 an (E)-3-hydroxyprop-1-enyl chain stiffened by its double bond. This chain reproduces the lateral hydroxyl of the non-classical cannabinoids of the CP series, which makes AM-4030 the example of the hybrid category in the UNODC manual. The available literature is narrow and concerns receptor binding: Thakur et al. separated in 2002 the enantiomers of a new ligand with a restricted southern chain, which the secondary literature identifies as AM-4030, and showed that the levorotatory isomer has an exceptionally high affinity for CB1, with a selectivity of about seven-fold over CB2. The functional efficacy specific to AM-4030 is not documented, and nothing allows it to be deduced from that of HU-210, a full CB1 agonist from which it differs by its hexahydro nucleus and by the chain at position 6. No human data, no pharmacokinetic, metabolism or toxicology study has been published, and UNODC indicates that no compound of this category had been seized in 2013.

Source

An entirely synthetic molecule, absent from hemp and from any living organism. It belongs to the Makriyannis laboratory's series of classical/non-classical hybrids, which graft the CP-55,940-type hydroxyalkyl chain onto a hexahydrocannabinol skeleton to explore the role of this hydroxyl in cannabimimetic activity (Tius 1995). UNODC cites it as an example of this category in its manual for analysis laboratories, specifying that no compound of this category had been seized there (2013 edition).

No biological pathway: AM-4030 comes from no plant and has no known natural precursor. It is obtained by total chemical synthesis, within the family of classical cannabinoids with a benzo[c]chromene ring.

European Union

AM-4030 is not among the substances named in the annex of Framework Decision 2004/757/JHA as supplemented by Directives (EU) 2017/2103, 2019/369, 2020/1687, 2021/802, 2022/1326 and 2025/2062, nor in Schedule II of the 1971 Convention (Green List of the International Narcotics Control Board, 35th edition, 2024). No control measure of the Union's own targets it. Its status therefore varies between Member States, several of which apply generic definitions of chemical families liable to cover benzo[c]chromene derivatives.

France

AM-4030 is named nowhere in the consolidated list of ANSM (updated 16 February 2026), whereas its neighbours HU-210 and HU-243 are named in annex IV. It is covered, at best, by the generic clause of that annex, stemming from the decisions of 22 May and 3 June 2024 (classification applicable from 3 June 2024): “any substance derived from the benzo[c]chromene nucleus”, non-, partially or fully hydrogenated on ring A, substituted notably at position 1 by a hydroxyl, at position 3 by an alkyl chain, at position 6 by “one or two alkyl groups” and at position 9 by a hydroxyalkyl function, excluding cannabinol (CBN), cannabinolic acid, THCV and THCVA below 0.3 % and THCA below the legal content. AM-4030 meets these criteria at positions 1 (hydroxyl), 3 (1,1-dimethylheptyl) and 9 (hydroxymethyl), and bears a methyl at position 6, but that position also bears an (E)-3-hydroxyprop-1-enyl chain, alkenyl and not alkyl: a literal reading of the clause does not settle this point, and its application to AM-4030 remains to be confirmed. The entry covering tetrahydrocannabinols, their esters, ethers and salts (annex III since the decision of 6 February 2026) does not concern it, the molecule being a substituted hexahydrocannabinol.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

Family

Synthetic CB receptor agonist › Research ligand or medicine

Class

classical

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

AM-4030 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

1. 1Thakur et al., Journal of Biochemical and Biophysical Methods, 2002: enantiomeric resolution of a novel chiral cannabinoid ligand with a restricted southern chain (levorotatory isomer: roughly seven-fold CB1/CB2 selectivity) (new tab)PMID 12543516
2. 2Tius et al., Life Sciences, 1995: classical/non-classical hybrids, stereochemical requirements of the southern hydroxyalkyl chain (new tab)PMID 7776825
3. 3Drake et al., Journal of Medicinal Chemistry, 1998: classical/non-classical hybrids with a functionalised southern chain (C-6β methyl, ethyl, propyl analogues) (new tab)PMID 9733485
4. 4Tettey et al. (UNODC), Forensic Science International: Synergy, 2021: recommended methods for the identification and analysis of synthetic cannabinoid receptor agonists (AM-4030 cited as an example of a hybrid cannabinoid, CAS 587023-54-9) (new tab)PMID 33665591
5. 5UNODC, Recommended methods for the identification and analysis of synthetic cannabinoid receptor agonists in seized materials (ST/NAR/48), 2013: « hybrid cannabinoids, e.g. AM-4030 »; no compound in this category seized (new tab)
6. 6ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026, annex IV: « any substance derived from the benzo[c]chromene nucleus » clause (decisions of 22 May and 3 June 2024) (new tab)
7. 7ANSM, ANSM adds new cannabinoids to the narcotics list, in force on 3 June 2024 (new tab)
8. 8INCB, Green List of psychotropic substances under international control, 35th edition, 2024 (Schedule II: AM-4030 absent) (new tab)
9. 9PubChem, AM-4030, CID 10550598 (identifiers, structure, CAS 587023-54-9) (new tab)

SMILES

CCCCCCC(C)(C)C1=CC2=C([C@@H]3C[C@@H](CC[C@H]3[C@](O2)(C)/C=C/CO)CO)C(=C1)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.